Results 261 to 270 of about 41,710 (302)
Some of the next articles are maybe not open access.
Dipeptidyl peptidase 4 inhibitor‐associated mucous membrane pemphigoid
The Journal of Dermatology, 2021AbstractDipeptidyl peptidase 4 inhibitors (DPP‐4i) are associated with an increased risk of developing bullous pemphigoid (BP) in patients with diabetes. Autoantibodies targeting epitopes on the processed BP180, 120‐kDa (LAD‐1), and 97‐kDa (LABD97) linear immunoglobulin (Ig)A dermatosis antigens are the major autoantibodies in DPP‐4i‐associated BP ...
Mei Suezawa +8 more
openaire +2 more sources
Dipeptidyl-Peptidase 4 (DPP4) Inhibitors
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...Kimberly C. McKeirnan +1 more
+4 more sources
Dipeptidyl peptidase-4 inhibitors
2016Dipeptidyl peptidase (DPP)-4 inhibitors inhibit the activity of the enzyme responsible for the initial rapid degradation of the incretin hormones, thereby enhancing their antihyperglycemic effects.
openaire +1 more source
Effect of dipeptidyl peptidase‐4 inhibitors on complement activation
Diabetes/Metabolism Research and Reviews, 2020AbstractBackgroundAdverse activation of the complement cascade in the innate immune system appears to be involved in development of vascular complications in diabetes. Dipeptidyl peptidase‐4 (DPP‐4) is a cell surface serine protease expressed in a variety of tissues.
Ingeborg T. Hoffmann‐Petersen +7 more
openaire +3 more sources
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Clinical Pharmacokinetics, 2012Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique form of disease management for persons with type 2 diabetes mellitus. The aim of this review is to compare the clinical pharmacokinetics of available DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin) for the purpose of identifying ...
Larry K, Golightly +2 more
openaire +2 more sources
Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
Clinical Therapeutics, 2011Oral glucose-lowering agents are used to treat patients with type 2 diabetes mellitus (T2DM). Most patients require multiple agents to maintain glycemic targets. Dipeptidyl peptidase-4 (DPP-4) inhibitors are administered as monotherapy and in combination therapy for the treatment of T2DM.The aim of this article was to provide a thorough review of ...
Kathleen R, Richard +2 more
openaire +2 more sources
Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
Current Opinion in Nephrology and Hypertension, 2015Dipeptidyl peptidase-4 (DPP-4) inhibitors are incretin-based drugs approved for the treatment of type 2 diabetes. The main action of DPP-4 inhibitors is to increase the level of incretin hormones such as glucagon-like peptide-1 (GLP-1), thereby stimulating insulin secretion from pancreatic β cells.
Yuichi, Makino +2 more
openaire +2 more sources
Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors
Bioorganic & Medicinal Chemistry Letters, 2009The synthesis and biochemical evaluation of novel cyanothiazolidine inhibitors of dipeptidyl peptidase 4 (DPP4) is described. Their main structural feature is a constrained bicyclic core that prevents the intramolecular formation of inactive cyclic species.
Juan M, Betancort +12 more
openaire +2 more sources
Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience
Diabetes Technology & Therapeutics, 2012According to the latest American Diabetes Association guidelines, lowering glycated hemoglobin (HbA(1c)) to below or around 7% has been shown to reduce microvascular and neuropathic complications of diabetes and, if implemented soon after the diagnosis of diabetes, is associated with long-term reduction in macrovascular disease. Recently a new class of
DEROSA, GIUSEPPE, MAFFIOLI, PAMELA
openaire +3 more sources